Tag Archives: Moody's

Is the Worst of the Patent Cliff Behind Us?

By Amy Ritter. In a bit of good news for pharma, Moody’s Investors Service has upgraded its outlook for the global pharmaceutical industry to stable. The Moody’s rating reflects expectations for fundamental business conditions in the industry over the next 12 to 18 months, and until now, the industry had been limping along under a […]
Posted in Op-Ed | Also tagged , , , | 1 Comment
  • Categories

  • Meta